INSPIRATION HEALTHCARE GROUP PLC

Regulatory Filings • Nov 16, 2020

National Storage Mechanism | Additional information

RNS Number : 3418F

Inspiration Healthcare Group PLC

16 November 2020

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Project WAVE - MHRA Approval

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company is pleased to announce that it has received confirmation from the Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with clinical testing for the respiratory device it has designed for use in neonatal intensive care known as Project WAVE.

Initial trials are now expected to begin in the next few months at the Trevor Mann Baby Unit, Brighton & Sussex University Hospital (Royal Sussex). The Company acquired the technology for Project WAVE, a non invasive device to support breathing in premature infants, under a licence agreement in 2018 from a leading U.S. West Coast University and the project was granted a patent by the U.S. Patent Office in March 2020.

Neil Campbell, Chief Executive Officer, commented: "We are delighted to have passed this regulatory hurdle and getting Wave one step further in its development and are all looking forward to beginning our work with the neonatal team at the Royal Sussex to demonstrate the efficacy of this important new technology and approach in neonatal care." 

Enquiries:

Inspiration Healthcare Group plc Neil Campbell, Chief Executive Officer Jon Ballard, Chief Financial Officer	Tel: 01455 840555
Nominated Adviser & Broker Cenkos Securities plc Mark Connelly Stephen Keys Cameron MacRitchie	Tel: 0207 397 8900
Cadogan PR                                                                                          Alex Walters alex.walters@cadoganpr.com	Tel: 07771 713608

About Inspiration Healthcare http://www.inspiration-healthcare.com

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

Through investment in research and development the Company has six key own-brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally, the Company has a range of products for maintaining normothermia pre- during and post-surgery.

In September 2019, the Company acquired Vio Holdings a designer, manufacturer and supplier of single-use respiratory products and sterile medical consumables for £4 million and in June 2020 the Company acquired SLE, a leading global provider of neonatal ventilation products for £18 million.   Over 90% of SLE's revenues are generated from sales outside of the UK with a significant proportion of these in the Asia Pacific and the Middle East. When combined, the Group generates approximately 60 per cent. of its revenue from exports.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the U.K. and Ireland, the Company has a direct sales team selling Inspiration Healthcare Branded and complementary products from third parties, with an additional range of home healthcare products.  This is supported by Technical Support for planned preventative maintenance and emergency assistance.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAVXLFFBFLFFBD